Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Olema PharmaceuticalsOLMA -1.12%30 Cash-to-Debt is 125.98 as of Jun. 2026, which is 4% above its 10-year median of 121.21. GuruFocus rates OLMA with a GF Score™ of 30/100. The stock has 3 warning signs investors should review. Among 1,393 Biotechnology companies, Olema Pharmaceuticals ranks better than 78.1% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Olema Pharmaceuticals's cash to debt ratio for the quarter that ended in Jun. 2026 was 125.98.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Olema Pharmaceuticalscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Olema Pharmaceuticals's Cash-to-Debt or its related term are showing as below:
OLMA'
s Cash-to-Debt Range Over the Past 10 Years
Min: 73.46 Med: 121.21 Max: No Debt
Current: 125.98
During the past 8 years, Olema Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 73.46. And the median was 121.21.
OLMA's Cash-to-Debt is ranked better than 78.1% of 1393
companies
in the Biotechnology industry
Industry Median: 7.03
vs OLMA: 125.98
Olema Pharmaceuticals (NAS:OLMA) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Olema Pharmaceuticals Cash-to-Debt Related Terms
Olema Pharmaceuticals Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Olema Pharmaceuticals's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Olema Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Olema Pharmaceuticals Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Olema Pharmaceuticals's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Olema Pharmaceuticals's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Olema Pharmaceuticals (OLMA) has a Cash-to-Debt of 125.98 as of Jun. 2026. This is near median its historical median of 121.21. Over the past decade, Olema Pharmaceuticals' Cash-to-Debt has ranged from 73.46 to 10,000.00. According to the industry distribution chart, Olema Pharmaceuticals ranks #305 out of 1393 companies in the Biotechnology industry, placing it in the top 21.9%.
Is Olema Pharmaceuticals' Cash-to-Debt too high?
Olema Pharmaceuticals' current Cash-to-Debt of 125.98 is near median its 10-year median of 121.21. Over the past 10 years, this metric has ranged from a low of 73.46 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 7.03. Olema Pharmaceuticals' value of 125.98 is 1692% above this industry median. Based on the distribution chart, Olema Pharmaceuticals ranks #305 out of 1393 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Olema Pharmaceuticals has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Olema Pharmaceuticals' Cash-to-Debt compare to ATTO and TBPH?
According to the Biotechnology industry distribution chart, Olema Pharmaceuticals ranks #305 out of 1393 companies for Cash-to-Debt. This places Olema Pharmaceuticals in the top 22% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 7.03. Olema Pharmaceuticals' value of 125.98 is 1692% above this benchmark. Historically, Olema Pharmaceuticals' own Cash-to-Debt has ranged from 73.46 to 10,000.00 over the past decade. While the company's 10-year median is 121.21 vs. the industry median of 7.03, Olema Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.03, based on 1,393 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Olema Pharmaceuticals's current Cash-to-Debt of 125.98 is 1692% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Olema Pharmaceuticals's current Cash-to-Debt is 125.98, which is near median its own 10-year median of 121.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Olema Pharmaceuticals stock overvalued right now?
Olema Pharmaceuticals (OLMA) has a current Cash-to-Debt of 125.98. The current Cash-to-Debt is 125.98, which is near median its 10-year median of 121.21 and 1692% above the Biotechnology industry median of 7.03. Olema Pharmaceuticals' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Olema Pharmaceuticals (OLMA), the current Cash-to-Debt is 125.98 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
30GF Score
Get the complete analysis for OLMA
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OLMA has been successfully added to your 
